AGM Statement

Deltex Medical Group PLC
29 May 2002


29 May 2002


            Deltex Medical Group plc ('Deltex Medical' / 'Company')

                                   AGM STATEMENT


2001 was a year of growth for Deltex Medical in all areas of its business.  We
grew our installed base of monitors, we increased the number of probes that were
used on the monitors in place and we expanded the number of countries in which
our products are sold.

It is worth remembering that, during 2001, some 18,000 people got better quicker
as a result of doctors treating their patients with the help of our equipment.
This is equivalent to 50 patients every day and this number is increasing.

We continue to make progress in the current year with new sales in all our major
markets including Japan and Korea and we have made our first sales in South
America.

We are preparing for 1 July 2002, when we take over our own direct distribution
in the UK market and we are building our team to fulfill this opportunity.  Our
new theatre probe, which substantially lowers the cost of using our technology,
will be available in the market from the same date.  We anticipate that this
launch will give our new sales force an additional exciting product to help them
make a strong entry into the market.

Our training courses for doctors, which are organised by the Middlesex Hospital
in London, continue to be over-subscribed and we have for the first time
arranged a similar course outside London which was also very well attended.

We are now gaining the benefit of the cost savings which we made in 2001 and
this has brought our monthly cash utilisation in line with our forecast.

Our task for the remainder of the year is to implement aggressively the many
opportunities which we have generated for the business to allow it to grow its
sales and marketing activities rapidly.  We are confident that we will do this
successfully thus consolidating our lead in the important and growing field of
haemodynamic optimisation.


Nigel Keen
Chairman and Chief Executive



Enquiries

Deltex Medical Group plc
Tel: [phone]

Nigel Keen, Chairman and Chief Executive
[e-mail]
Ewan Phillips, Finance Director
[e-mail]

Financial Dynamics
Tel: [phone]

Stephanie Highett
[e-mail]
Sarah Mehanna
[e-mail]



Notes for editors

Deltex Medical primarily develops, assembles and markets a cardiac function
monitor and therapy guidance device, the CardioQ ('CardioQ'/'Monitor'). The
CardioQ incorporates the Company's proprietary software and a narrow,
easy-to-use, minimally invasive, disposable oesophageal probe, used for
transmitting and receiving an ultra-sound ('Doppler') signal. By using this
Doppler technology, the CardioQ provides clinicians with an early warning on the
haemodynamic condition of critically ill patients. This continuous, real-time
monitoring facilitates the administration of fluids or drugs in a timely fashion
and provides an immediate assessment of their impact.

There are already over 600 CardioQs currently in use in hospitals worldwide and
distribution arrangements are in place in over 30 countries. In addition, there
are currently more than 75 clinical publications on the use of the CardioQ which
have repeatedly:-

  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works
  • proved that the CardioQ works over a variety of types of operation
  • shown that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The Company is also currently developing a number of new products:-

  • A multi-patient probe for use in specific circumstances in certain markets
  • The SupraQ - a monitor based on the CardioQ technology but using a
    completely non-invasive probe; the prototype is being prepared for clinical
    testing in the second half of 2002
  • The NeuroQ - a monitor designed to measure blood flow in the brain; the
    new prototype is in preparation for clinical trials in the second half of
    2002
  • The multi-patient probe for use in operating theatres in the UK will be
    launched in July 2002.




                      This information is provided by RNS
            The company news service from the London Stock Exchange